4120 Stock Overview
A pharmaceutical company, develops and manufactures drugs worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Orient EuroPharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$48.10 |
| 52 Week High | NT$58.00 |
| 52 Week Low | NT$36.70 |
| Beta | 0.45 |
| 1 Month Change | -0.10% |
| 3 Month Change | -3.22% |
| 1 Year Change | 23.33% |
| 3 Year Change | 33.61% |
| 5 Year Change | -13.02% |
| Change since IPO | 281.99% |
Recent News & Updates
Recent updates
Here's Why Orient EuroPharma (GTSM:4120) Has A Meaningful Debt Burden
Apr 04
Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) 3.3% Dividend Worth Your Time?
Mar 04A Look At Orient EuroPharma's (GTSM:4120) Share Price Returns
Feb 10Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) Recent Performancer Underpinned By Weak Financials?
Jan 22We Think Orient EuroPharma (GTSM:4120) Can Stay On Top Of Its Debt
Jan 04
A Look At The Fair Value Of Orient EuroPharma Co., Ltd. (GTSM:4120)
Dec 17Are Dividend Investors Getting More Than They Bargained For With Orient EuroPharma Co., Ltd.'s (GTSM:4120) Dividend?
Nov 29Shareholder Returns
| 4120 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.8% | -0.01% | -2.1% |
| 1Y | 23.3% | -2.7% | 25.6% |
Return vs Industry: 4120 exceeded the TW Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: 4120 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 4120 volatility | |
|---|---|
| 4120 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4120 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4120's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | n/a | Peter Tsai | www.oepgroup.com |
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name.
Orient EuroPharma Co., Ltd. Fundamentals Summary
| 4120 fundamental statistics | |
|---|---|
| Market cap | NT$4.17b |
| Earnings (TTM) | NT$190.91m |
| Revenue (TTM) | NT$4.47b |
21.9x
P/E Ratio0.9x
P/S RatioIs 4120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4120 income statement (TTM) | |
|---|---|
| Revenue | NT$4.47b |
| Cost of Revenue | NT$2.31b |
| Gross Profit | NT$2.17b |
| Other Expenses | NT$1.97b |
| Earnings | NT$190.91m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.20 |
| Gross Margin | 48.44% |
| Net Profit Margin | 4.27% |
| Debt/Equity Ratio | 77.8% |
How did 4120 perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield45%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 07:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orient EuroPharma Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaowei Huang | Masterlink Securities Corp. |